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Abstract
Chronic obstructive pulmonary disease (COPD) represents a significant burden for healthcare systems that is
expected to grow further in the future. Inhaled long-acting bronchodilators, including tiotropium, represent the
cornerstone of management of COPD patients. Economic studies evaluating the cost-effectiveness ratio of inhaled
bronchodilators have to take into account several parameters, including the reduction of COPD exacerbations and
related hospitalizations, as well as disease modification and improvement in quality of life and mortality. At an era
when the healthcare resources are unlikely to grow as quickly as demand, economic analyses remain the corner-
stone for the justification of the broad use of medication with an acceptable cost-effectiveness ratio. The greatest
importance of such studies in COPD is the identification of subgroups of patients that will have the most benefit
with an acceptable cost-effectiveness ratio for the healthcare providers. The development of models that will incor-
porate a global evaluation of the different aspects of this multi-component disease, in order to provide the best
available care to each individual patient is urgently needed.
Chronic obstructive pulmonary disease (COPD) repre-
sents a major cause of morbidity and mortality world-
wide, with a significant economic burden for health
systems and individual patients, both in high and in low
income countries. According to the WHO Global Burden
of Disease Project, COPD was the fifth leading cause of
disease in 2001 and is expected to become the third lead-
ing cause by 2020 [1]. In this same report, COPD was
also estimated to be among the ten leading causes of dis-
ability-adjusted life years in all countries [1]. The ageing
of global population, along with the continued increase
in the use of tobacco, especially in developing countries,
represent the major causes for the expected increase in
the burden of COPD [2]. The estimation of the overall
cost of COPD for healthcare systems represents a major
challenge, since both direct costs (including medication,
medical equipment and hospital admissions) and indirect
costs (including loss of work and productivity, disability
and premature death) can be included [3]. Several
confounding factors, including co-morbid diseases and
socioeconomic differences, account for the reported var-
iation in the annual cost of COPD between countries,
ranging from as low as €151 for mild COPD in Italy to
more than $ 10,000 for severe COPD in the U.S. [3,4]. It
is now well-documented that a major contributor to the
excessive cost of COPD for healthcare systems, especially
in advanced disease, is due to the burden of COPD
exacerbations (ECOPD) and especially the subsequent
hospitalizations [5]. Most importantly, economic studies
suggest that this burden of COPD may further grow in
the future [6].
Inhaled long-acting bronchodilators represent the cor-
nerstone of current management of COPD [7,8], provid-
ing improvement in significant patient-centered
outcomes [9]. Several cost-effectiveness analyses of
inhaled bronchodilators have been undertaken in order
to justify reimbursement of those drugs by healthcare
systems for the management of COPD patients, with
contradictory results [10-14]. A 5-year cost-effectiveness
analysis of tiotropium, salmeterol and ipratropium for
the management of COPD in Spain suggested that tio-
tropium demonstrated the highest expected net benefit,
if decision makers can afford to spend additional budget
to gain additional health benefits, as expressed by
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quality-adjusted life-years [13]. In the accompanying
paper of this commentary, Neyt and co-workers are to
be congratulated for undertaking quite an amount of
work in order to perform a cost-effectiveness analysis of
the use of tiotropium in a large longitudinal observa-
tional database of patients from the Belgian Health
System [15]. A model applying the relative treatment
effect of the 4-year Understanding the Potential Long-
term Impacts of Tiotropium (UPLIFT) trial on this
population led to an unfavorable cost-effectiveness ratio
for tiotropium, based on the reduction of the baseline
risk of COPD exacerbation and exacerbation-related
hospitalizations [15].
Differences in study design and definitions along with
differences between healthcare systems may account for
the observed differences between the study of Neyt et al.
and previous ones, yet several factors have to be taken
into account. COPD exacerbations represent a signifi-
cant outcome in all major COPD therapeutic trials
[16,17] and have a significant impact on mortality [18]
and the outcome of individual patients [19]. Long-acting
bronchodilators have been shown to reduce effectively
COPD exacerbations and exacerbation-related hospitali-
zations [16,17], but this hardly represents the spectrum
of improvements in everyday life of COPD patients that
those agents provide. Tiotropium, specifically, has been
shown to improve pulmonary function, dyspnea, exer-
cise capacity and health-related quality of life in COPD
patients, both in short-term [20,21] and in long-term
[17] trials. There is additional evidence from post-hoc
analyses of the UPLIFT trial that tiotropium reduces all-
cause mortality and cardiovascular mortality and events
in COPD patients[22], and may even reduce the rate of
decline of FEV1 in patients with GOLD Stage II COPD
[23], therefore modifying the natural history of the
disease. Such outcomes are difficult to be incorporated
in economic models. This is even more important since
the proper definition of COPD exacerbations is still
under debate between clinicians [24], and such events
are highly underperceived and undertreated by indivi-
dual patients [25].
Disease severity represents another important para-
meter that needs to be considered in the evaluation of
efficacy of inhaled medication. The cost-effectiveness of
tiotropium has been previously shown to be more favor-
able in more severe disease and in patients with pre-
vious hospitalizations [14]. In the study of Neyt et al.
there was no analysis according to disease severity, yet
the authors recognized that patients with previous hos-
pitalizations for COPD exacerbations are the ones who
may benefit from tiotropium treatment [15]. In a recent
prospective economic analysis of a study that included
patients with moderate-to-severe COPD with at least
one exacerbation requiring medical intervention in the
year before randomization, tiotropium proved to be the
most cost-effective option, compared to the addition of
salmeterol or salmeterol/fluticasone combination,
despite a reduction in hospitalizations and an improve-
ment in quality of life in patients receiving the combina-
tion treatment [10].
Besides the fact that Neyt and colleagues evaluated
only a single outcome (i.e. the reduction in of exacerba-
tions and exacerbation-related hospitalizations) in their
cost-effectiveness analysis and they did not provide data
according to disease severity, their study presents
further limitations. The short-term horizon of one year
chosen by the authors may not be enough for the
appropriate evaluation of adverse events, given the low
rate of COPD exacerbations per year reported in all the
large trials [16,17], that was further confirmed in the
Neyt study [15]. Moreover, the definition of this study
for the use of tiotropium “on a more regular basis”,
including patients with ≥90 daily defined doses per year,
suggests that several of the included patients were not
compliant with their treatment. This is extremely
important, since there is now evidence from the
TORCH trial that adherence to inhaled drugs (as
defined by >80% use of study medication) is associated
with reduced risk of death and admission to hospital
due to exacerbations in COPD [26].
In the last decade our understanding of COPD patho-
genesis, natural history and treatment has improved sig-
nificantly. A major part of this improvement is due to
the fact that we have evaluated the effectiveness of treat-
ments on patient-centered outcomes beyond the corner-
stone measure of FEV1. In that time-course, we have
learned that inhaled corticosteroids may reduce exacer-
bations [27], and even from the beginning there was a
concern about high treatment costs with those drugs
[28]. We have additionally learned that long-acting
bronchodilators provide a lot more than bronchodila-
tion, especially in the long-term [17], yet those drugs
have a higher cost compared to short-acting bronchodi-
lators [7]. Pulmonary rehabilitation has a favorable cost-
effectiveness ratio [29], in contrast to lung-volume
reduction surgery, even in highly selected patients [30].
Yet, all those interventions have contributed to an
improvement in survival of COPD patients, that reflects
overall better disease management in the last decade
[31]. The main message from economic analyses
remains the same: “the more you spent, the more you
save”. But where lays the thin line of cost-effectiveness?
Probably somewhere between the lowest possible cost
and the optimal treatment selection for each patient.
In a multi-component disease, such as COPD, many
parameters have to be addressed in order to evaluate
globally the individual patients and recognize possible
therapeutic phenotypes [32]. Despite the fact that
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interventions aiming at the cost-effective early identifica-
tion of new COPD cases [33] and the reduction of
exacerbations will have the most impact on costs of
COPD over the next 20 years [6], several other para-
meters, including comorbidities and quality of life, have
to be constantly taken into account. At an era when the
healthcare resources are unlikely to grow as quickly as
demand, economic analyses remain the cornerstone for
the justification of the broad use of medication with an
acceptable cost-effectiveness ratio. The greatest impor-
tance of such studies in COPD is the identification of
subgroups of patients that will have the most benefit
with an acceptable cost-effectiveness ratio for the
healthcare providers. What is urgently needed is the
development of models that will incorporate a global
evaluation of the different aspects of this multi-compo-
nent disease, in order to provide the best available care
to the individual patient.
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